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Among the three major POU proteins expressed in
human skin, Oct-1, Tst-1/Oct-6, and Skn-1/Oct-11, only
the latter induced SPRR2A, a marker of keratinocyte
terminal differentiation. In this study, we have identi-
fied three Skn-1 isoforms, which encode proteins with
various N termini, generated by alternative promoter
usage. These isotypes showed distinct expression pat-
terns in various skin samples, internal squamous epithe-
lia, and cultured human keratinocytes. Skn-1a and Skn-
1d1 bound the SPRR2A octamer site with comparable
affinity and functioned as transcriptional activators.
Skn-1d2 did not affect SPRR2A expression. Skn-1a, the
largest protein, functionally cooperated with Ese-1/
Elf-3, an epithelial-specific transcription factor, previ-
ously implicated in SPRR2A induction. This cooperativ-
ity, which depended on an N-terminal pointed-like
domain in Skn-1a, was not found for Skn-1d1. Actually,
Skn-1d1 counteracted the cooperativity between Skn-1a
and Ese-1. Apparently, the human Skn-1 locus encodes
multifunctional protein isotypes, subjected to biochem-
ical cross-talk, which are likely to play a major role in
the fine-tuning of keratinocyte terminal differentiation.
The epidermis constitutes the interface between the orga-
nism and the environment and provides protection against
physical, chemical, and microbial damage. The major epider-
mal cell type, the keratinocyte, engages in a tightly regulated
process of terminal differentiation, which is essential for the
protective barrier of the skin and is reflected in vivo by the
multilayered structure of the epidermis. The innermost layer
(stratum basale), connected to the dermis, comprises undiffer-
entiated keratinocytes with a high proliferative potential. The
cells committed to terminal differentiation migrate outwards
into the non-dividing suprabasal layers and undergo distinct
morphological and structural changes (for review, see Ref. 1).
The transition from proliferating basal keratinocytes to termi-
nally differentiated cells is accompanied by a significant alter-
ation in the gene expression program. The repression of genes
required for cellular growth contrasts with the induction of
genes related to cell death and cornification. Aberrations in
this tightly choreographed process will affect the expression of
epidermal structural proteins, such as those involved in the
formation of cytoskeleton, desmosomes, and cornified cell en-
velopes. As a matter of fact many genetic and acquired human
dermatoses have been linked to mutations or aberrant expres-
sion of these proteins (2, 3).
Whereas the importance of structural proteins in safeguard-
ing the integrity of epidermis and internal squamous epithelia
is becoming well understood, little is yet known about the
regulatory processes that are involved. Although ubiquitous
transcription factors contribute to keratinocyte-specific gene
expression (4–7), the complex balance between proliferation,
stratification, and cornification is likely to be coordinated by
cell type-specific proteins. Good candidates for such a function
are the POU domain transcription factors, a family of more
than 40 homeodomain-containing proteins involved in cell dif-
ferentiation and tissue specification (8, 9). The characteristic
POU domain consists of two conserved regions, a POU-specific
domain and a POU homeodomain, connected by a hypervari-
able linker region. The entire POU domain is required for DNA
binding. The octamer 5-ATGCAAAT-3 is the most frequent
target for POU domain proteins (10).
Major POU domain factors in skin are Oct-1, Tst-1/Oct-6,
and Skn-1/Oct-11 (11). The ubiquitous Oct-1 is expressed in
both proliferating and differentiating epidermal keratinocytes,
whereas Oct-6 and Skn-1 are primarily expressed in supra-
basal layers. Skn-1 is selectively expressed in the epidermis
(12–15). In vivo ablation of murine Skn-1 did not reveal a
specific function for this gene, mainly due to redundancy with
Oct-6 (12). Recently however, the use of in vitro raft cultures
disclosed a regulatory role of Skn-1 in keratinocyte prolifera-
tion and differentiation (16).
A further degree of regulatory complexity is due to the fact
that at least several POU genes give rise to various isoforms,
with specific functional properties and expression patterns (e.g.
Oct-1, Oct-2, Brn-3, and Pit-1) (8). Also, the rat Skn-1 gene was
shown to generate two functionally distinct transcripts, Skn-1a
and Skn-1i (13). Here we show that the human homologue
expresses three isoforms that differentially affected the expres-
sion of the SPRR2A cornified envelope precursor gene, a
marker of keratinocyte terminal differentiation, whose regula-
tion has been extensively studied (5, 17). This isotype-specific
selectivity in SPRR2A regulation, which varied from activation
to repression, depended on the differential interaction of the
Skn-1 isoforms with the epithelium-specific Ets factor Ese-1
(18).
EXPERIMENTAL PROCEDURES
Screening of a Keratinocyte cDNA Library—A human keratinocyte
cDNA library constructed in Lambda ZAP II (Stratagene) (19) was
screened with probes from the POU domains of Oct-1 and Oct-2 (20, 21)
at a stringent hybridization temperature. This yielded among others
two independent Skn-1 clones. Plasmid DNA was isolated by in vivo
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excision with Exassist M13 helper phage (Stratagene).
5-Rapid Amplification of cDNA Ends (RACE)1—5-RACE was per-
formed on poly(A) RNA isolated from cultured normal human kerati-
nocytes essentially according to a previously described method (22).
Briefly, cDNA synthesized from 1 g of poly(A) RNA, primed with a
5-biotinylated antisense oligonucleotide specific for Skn-1 (5-biotin-
GAAACCTCTTCTCCAGAGTCAGGCGG), was purified on Dynabeads
coated with streptavidin (Dynal) and ligated to a 5-phosphorylated and
3 3-amino-2-propanol-ether-blocked RACE-anchor (5-phosphate-GC-
GGCCGCGTCGTGACTGGGAAAACCCOCH2CHOHCH2NH2). PCR
primed with various reverse Skn-1 primers (1, ACCAAATACTTCACT-
GAGGCTGGGGTAGGAG; 2, AACCGCCGCAGCCCCACATCTCCCT
GT; 3, GAGGAGACCGCTTTGTTGCTGTGGA; positions in GenBankTM
accession number AF133895 are 814, 631, and 394, respectively) and a
RACE primer complementary to the anchor (GGGTTTTCCCAGTCAC-
GACGCGGC) was performed with a 2.5:1 mixture of Pwo polymerase
(Roche Applied Science) and Taq polymerase (HT Biotechnology Ltd.)
for 40 cycles (20 min at 94 °C, 30 min at 50–60 °C, 2 min at 72 °C).
Fragments were cloned in pBluescript II SK() (Stratagene).
Inverse PCR—Genomic DNA was isolated from either simian COS-1
cells or mouse 3T3 fibroblasts by proteinase K digestion and phenol
extraction. One g of DNA was digested with either BstYI or Sau3AI
and ligated with T4 DNA ligase (Amersham Biosciences). Ligated DNA
was used in a PCR reaction with primers designed to contain restriction
sites at the 5 end to facilitate subsequent cloning (simian sense primer,
CGAATTCCCACAGACTGG GCCGGGACT; mouse sense primer,
AGAATTCCCACAGACAGGGCCTGGCCT, derived from the mouse
cDNA sequence (GenBankTM accession number Z18537); common anti-
sense primer, AGAAAGCTTTGTTGCTGTGGAAAGG).
Semiquantitative RT-PCR and RNA Blotting—Trizol reagent (In-
vitrogen) was used to isolate total epidermal RNA from tissue obtained
either after breast reduction or circumcision. Total RNA (200 ng) was
reverse-transcribed with Super-RT (SphaeroQ) and random hexamers
(Amersham Biosciences). Semiquantitative PCR was performed accord-
ing to a previously published procedure (23) but using AmpliTaq Gold
(Roche Applied Science). The following isotype-specific Skn-1 primers
were used: Skn-1a: sense, CACAGATATCAAGATGAGTG, antisense,
TCTGAGATAGCAGGAACTG; Skn-1d1: sense, GTTGTAGCACATGT-
GTTTCA, antisense, GAAACCTCTTCTCCAGAGTCAG; Skn-1d2:
sense, TCACCTTAGAGGGAGGAGA, antisense, CAGCCGGGAGTTG-
TAGAC. This analysis resulted in products of 330, 581, and 590 base
pairs for Skn-1a, Skn-1d1, and Skn-1d2, respectively. Other primers
were: SPRR2A: sense, TGGTACCTGAGCATCGATCTGCC, antisense,
CCAAATATCCTTATCCTTTCTTGG (23); Ese-1: sense, CTGAGCAAA-
GAGTACTGGGACTGTC, antisense, CCATAGTTGGGCCACAGCCTC-
GGAGC. RT-PCR conditions for GAPDH were described previously
(24). All primers bridged introns, thus allowing a control for DNA
contamination. PCR products for the various Skn-1 isoforms were an-
alyzed on a blot with a probe covering most of the cDNA (generated with
the Skn-1a sense and the Skn-1d2 antisense primers). Sequence anal-
ysis was used to verify the identity of the various PCR products ob-
tained. SPRR2A RT-PCR products were identified with an SPRR2
cDNA probe (25). Ese-1 and GAPDH products were detected by
ethidium bromide staining. RNA dot-blots were probed with a 511-bp
KpnI/EcoRV fragment (3-UTR) of Skn-1 (GenBankTM accession num-
ber AF133895).
In Situ Hybridization—Experiments were carried out as described
previously (24). Digoxigenin-labeled (Roche Applied Science) sense and
antisense RNA probes were generated using the 511-bp KpnI/EcoRV
fragment (3-UTR) of Skn-1 described above, a 680-bp fragment of
SPRR2 (26), and a 475-bp XhoI/BglII fragment (3-UTR) of Ese-1 (Gen-
BankTM accession number U73844).
Expression Plasmids—Protein expression plasmids were constructed
by introducing the Skn-1 coding sequences in the HindIII and EcoRI
sites of the T7 expression plasmid pT7–2. Plasmids encoding the whole
open reading frame were generated for Skn-1a (pPOU117, from exon
1–13), Skn-1d1 (pPOU123, from codon A in intron 5 to exon 13), and
Skn-1d2 (pPOU121, exon 8–13). For Skn-1d1, 3 mutants were con-
structed either by site-directed mutagenesis (point mutations in
pPOU124 and pPOU118) or by PCR (pPOU137). Proteins encoded by
these plasmids were synthesized in a coupled in vitro transcription-
translation system (TNT reticulocyte lysate, Promega) in the presence of
[35S]methionine (Amersham Biosciences). Full-length Ets-2, Ese-1, and
Oct-2 cDNAs were isolated by screening the above-mentioned human
keratinocyte cDNA library either with Ets-specific (27) or Oct-1/2 POU
domain probes. For transfection the different cDNAs were cloned into
the RSV-H20 expression plasmid (28). Expression plasmids for Oct-1
and Oct-6 were gifts of Dr. W. Herr (Cold Spring Harbor) and Dr. D.
Meijer (Erasmus University Rotterdam), respectively.
Electrophoretic Mobility Shift Assay—Electrophoretic mobility shift
assays were performed as described in Fischer et al. (5). The SPRR2A
octamer oligonucleotide (GGATAAATTTGCATCTGGCT) was labeled
with T4 polynucleotide kinase, purified by denaturing gel electrophore-
sis and reverse-phase chromatography, and subsequently annealed to
the unlabeled complementary strand. In each reaction 2 l of pro-
grammed reticulocyte lysate and 20 fmol of labeled oligonucleotide
duplex were used.
Cell Culture, Transient Transfections, CAT and Luciferase Assays—
HaCaT cells were grown in DMEM with 10% bovine calf serum (Hy-
clone). Confluent cultures were transfected by incubating 5 cm culture
dishes for 2 h with 5 g of reporter plasmid (CAT or luciferase), 2.0 g
of Rous sarcoma virus expression plasmids (including compensating
amounts of empty Rous sarcoma virus vector), and 40 g of N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium salts transfection rea-
gent. Monolayers were washed with phosphate-buffered saline and
incubated for 24 h in culture medium. CAT assays were performed as
described (5). Luciferase activity was measured with the luciferase
assay system (Promega) essentially as previously described (28). All
transfections were performed at least in triplicate.
The SPRR2A minimal promoter-driven CAT plasmid pSG55 has
been previously described (5). Luciferase plasmids were constructed in
pGL3 (Promega) and contained the following SPRR2A promoter in-
serts, all derived from previously described plasmids (5): pSG350-wt
(minimal promoter), pSG55; pSG390-Ets mutant, pSG212; pSG527-
octamer mutant, pSG185.
RESULTS
Structural Characterization and Organization of Skn-1 Iso-
forms—Searching the human genome data base at NCBI with
the previously described human Skn-1a cDNA (GenBankTM
accession number AF133895) disclosed one sequence (Gen-
BankTM accession number AP 001150), encompassing the com-
plete human gene. The 2868-bp cDNA sequence comprises 13
exons and extends over a 70-kilobase genomic region (Fig. 1A).
The characteristic POU domain is encoded by exons 7–10.
The screening of a human keratinocyte cDNA library with a
POU domain probe and 5 RACE (see “Experimental Proce-
dures”) identified three Skn-1 isoforms, namely the previously
described Skn-1a (29) and two novel variants, Skn-1d1 and
Skn-1d2. Comparison with the genomic sequence revealed that
the 5 end of Skn-1d1 and Skn-1d2 corresponded to sequences
in introns 5 and 7, respectively (Fig. 1A). The absence of other
introns in these transcripts confirmed the mRNA origin of
both clones.
The human Skn-1d1 transcript is homologous to the Skn-1i
variant of rat (13) and is compared in Fig. 1B with the corre-
sponding simian and rodent sequences. The translation initia-
tion codon previously identified in the rat (codon 1) is not
present in the human sequence. Both primate genes contain an
AUG codon (codon A), which is in-frame with the Skn-1a coding
sequence. However, this start codon is not likely to be func-
tional since it is followed by a termination codon UAG (codon B)
that is not present in rodents. A putative low affinity initiation
codon CUG for Skn-1d1 is found at position 85 in the beginning
of exon 6 (codon C) (Fig. 1B).
The sequence of the Skn-1d2 transcript, which initiates in
intron 7, revealed 3 intron-encoded AUG codons in-frame with
the POU domain sequence but followed by a termination codon
at position 154 (Fig. 1C). Potential start codons for open read-
ing frames are found in exon 8 (codon D and/or codon E).
DNA Binding Activity of the hSkn-1 Variants—The integrity
of the Skn-1 expression plasmids and their coding potential
were verified by producing proteins in vitro with the TNT
reticulocyte lysate system (Promega) (Fig. 2B). Skn-1a (pPOU-
1 The abbreviations used are: RACE, rapid amplification of cDNA
ends; RT, reverse transcription; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; UTR, untranslated region; CAT, chloramphenicol
acetyltransferase.
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117) migrated at the predicted molecular mass (47.5 kDa) and
bound to the SPRR2A octamer site (Fig. 2C). The Skn-1d2
isoform (pPOU-121) generated two different products (Fig. 2B).
The slow migrating product has an apparent molecular mass of
25 kDa, which is in accordance with a protein initiating at
codon D in the POU-specific domain (Fig. 1C). The 21.5-kDa
product corresponds to a protein starting at initiation codon E.
None of these Skn-1d2 isoforms is capable of binding to the
SPRR2A octamer site (Fig. 2C), which is likely due to the
partial deletion of the POU-specific domain (Fig. 1A).
The wild type Skn-1d1 transcript (plasmid pPOU-123) codes
for a major polypeptide of 35 kDa and two minor products of 33
and 31 kDa (Fig. 2B). To investigate translational initiation of
Skn-1d1 proteins more precisely, constructs with mutations in
codons A, B, or C (Fig. 1B and 2A) were generated. Fig. 2B
shows that translation of the major Skn-1d1 polypeptide most
likely initiates at codon C (a weak CUG initiation codon).
Indeed, pPOU-137, in which this codon was changed into an
efficient AUG initiator, yielded high levels of a product of 35
kDa, identical to the largest polypeptide from the wild type
transcript. This cDNA was used in transfection experiments.
The minor 33- and 31-kDa proteins were not investigated
further.
Electrophoretic mobility shift assays were performed to com-
pare the binding affinity of Skn-1a (pPOU-117) and Skn-1d1
(pPOU-137) to the SPRR2A octamer site. Labeled double-
stranded SPRR2A octamer oligonucleotide was incubated with
reticulocyte lysate programmed with either Skn-1a or Skn-1d1.
As shown in Fig. 2D, competition with increasing amounts of
unlabeled binding site revealed that both Skn-1 variants bound
the SPRR2A octamer site with similar affinities.
Transactivation Potential of Skn-1 Isoforms—In Fig. 3A, the
SPRR2A proximal promoter, fused to the CAT reporter and
encompassing all cis-elements necessary for expression during
keratinocyte terminal differentiation (5), was transiently
transfected into HaCaT cells, which contain low levels of en-
dogenous POU proteins (16). We first evaluated the transacti-
vation potential of Oct-1, Oct-6/Tst-1, and Skn-1a, the major
POU domain proteins expressed in skin (11), and of Oct-2, a
lymphoid-specific transcription factor (21), also expressed in
cultured human keratinocytes (12).2 Oct-1 and Oct-2 did not
affect base-line expression of SPRR2A, Oct-6 repressed pro-
moter activity by 70%, and Skn-1a was the only POU domain
2 A. Cabral, D. F. Fischer, W. P. Vermeij, and C. Backendorf, unpub-
lished observation.
FIG. 1. A, genomic organization of the human Skn-1 gene. The transcription start sites for Skn-1a, Skn-1d1, and Skn-1d2 are indicated by arrows.
The POU-specific domain (POU-S) and the POU-homeodomain (POU-HD) of Skn-1a are represented. Exons are boxed, and introns are numbered.
kb, kilobases. B, part of human intron 5 is compared with the corresponding sequence from simian, rat (GenBankTM accession number L23863),
and mouse. Simian and murine sequences were obtained from inverse PCR on Cos-1 and 3T3 cells, respectively (“Experimental Procedures”). An
asterisk indicates the start of the longest 5-RACE clone for Skn-1d1. Bases shown in lowercase correspond to intronic sequences; various initiation
and termination codons that are discussed in “Results,” and the 3 splice-site of intron 5 is highlighted. C, sequence of the longest 5-RACE clone
for Skn-1d2. Potential initiation and termination codons are indicated. Intron sequences are shown in lowercase. The sequence of exon 8 is
underlined. The 3 splice site is represented in bold.
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protein tested that mediated gene activation (3–4-fold induc-
tion, Fig. 3A).
To investigate the relative contribution of the individual
Skn-1 isoforms in the regulation of the SPRR2A gene, the
transactivation potential of the three variants was determined
by transfecting increasing amounts of isotype-specific expres-
sion plasmids into HaCaT cells, programmed with an SPRR2A-
luciferase construct. Both Skn-1a and Skn-1d1 up-regulated
the SPRR2A promoter by 3–4-fold. The saturation kinetics
were, however, different because lower amounts of Skn-1a were
needed to reach a plateau, indicating that Skn-1a can transac-
tivate the SPRR2A promoter more efficiently than Skn-1d1
(Fig. 3B). Skn-1d2 had no effect on SPRR2A promoter activity,
even at higher doses. Collectively, these results indicate that
among several POU domain proteins only Skn-1a and Skn-1d1
are able to activate the SPRR2A promoter in an in vitro tran-
sient transfection experiment. Hence, it was important to in-
vestigate whether a similar direct relation existed also in vivo
between Skn-1a/d1 and SPRR2A expression.
Correlation between SPRR2A and Skn-1a Expression in
Vivo—Initially, a panel of 50 different RNA samples from var-
ious human tissues was analyzed with a Skn-1-specific probe
(3-UTR), which detects all isoforms. Skn-1 expression was
restricted to a few stratified squamous epithelia including ep-
idermis, cervix, and foreskin (results not shown). To compare
the expression pattern of the three human Skn-1 variants with
SPRR2A expression, semiquantitative RT-PCR with isotype-
specific primer sets was performed on RNA isolated from either
total skin, epidermis, foreskin, cervix, or cultured primary ke-
ratinocytes. RNA from uterus, which does not contain SPRR2A
transcripts (23), was used as a negative control. The results in
Fig. 4A show that Skn-1a was expressed in all squamous epi-
thelia (lanes 1–6 and 8) and in cultured keratinocytes (lane 7),
although at different levels. Expression of Skn-1d1 was more
heterogeneous, as it was not detected in the skin and cervix
samples from lanes 1 and 8, respectively. Relatively high ex-
pression levels of Skn-1d1 (already visible after 25 cycles) were
found in the epidermal RNAs from lanes 2, 3, and 5. Skn-1d2
expression was, in general, similar to the one of Skn-1a. The
absence of Skn-1 transcripts in uterus correlated well with the
absence of SPRR2A expression. However, no clear correlation
was found in the other samples between the expression level of
one of the Skn-1 isotypes and SPRR2A expression, indicating
the involvement of other transcription factors. Indeed, previous
work from our laboratory has shown that expression of
SPRR2A relied on interdependent regulatory promoter ele-
FIG. 2. DNA binding activity of in vitro synthesized Skn-1 iso-
types. A, plasmids used for in vitro transcription-translation. The
various mutations in Skn-1d1 are indicated. Nomenclature of codons A,
B, and C is according to Fig. 1B. B, SDS-PAGE analysis of in vitro
synthesized Skn-1 proteins. Reticulocyte lysates were programmed
with the indicated Skn-1 plasmid or with a control plasmid (pT7–2, lane
1). Molecular mass markers (Amersham Biosciences) are indicated in
the margin (in kDa). Skn-1d1- and Skn-1d2-specific products are
marked with asterisks. C, electrophoretic mobility shift assay of Skn-1-
programmed lysates (lanes 1–6) or un-programmed lysate (lane 7) with
the SPRR2A octamer site. D, affinity of Skn-1a or Skn-1d1 for octamer
binding; reticulocyte lysate containing identical amounts of either
Skn-1a or Skn-1d1 protein were incubated with 20 fmol of the 32P-
labeled SPRR2A octamer site and competed with the indicated molar
excess of unlabeled binding site.
FIG. 3. Effect of various POU proteins on SPRR2A promoter
activity. A, the SPRR2A-CAT reporter construct (pSG55) was either
transfected alone or together with expression plasmids for Oct-1, Oct-2,
Oct-6, and Skn-1a into HaCaT keratinocytes as described under “Ex-
perimental Procedures.” CAT activity was determined 24 h after trans-
fection as previously described (5) and was related to the basal activity
of pSG55. B, increasing amounts of Skn-1a, Skn-1d1, and Skn-1d2
expression plasmids were co-transfected with the SPRR2A-luciferase
reporter construct (pSG350), and luciferase activity was determined
24 h later essentially as previously described (28).
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ments, recognized by various classes of transcription factors
(5). Consequently, we have also monitored the expression of the
epithelial-specific Ets factor Ese-1, previously implicated in
SPRR regulation (18, 27). Expression of this gene was found in
all samples, including uterus (although at low levels). The
highest levels were found in the epidermal sample of lane 2, in
cultured keratinocytes (lane 7), and in cervix (lane 8). Again, no
strict correlation was found between the levels of Ese-1 and
SPRR2A expression (Fig. 4A).
To investigate whether Skn-1 and Ese-1 co-localize in vivo,
we monitored the stratum-specific expression of Skn-1, Ese-1,
and SPRR2A in sections of foreskin (Fig. 4B). Whereas Skn-1
(the 3-UTR probe used detects all isoforms) was present in
most suprabasal layers, Ese-1 expression was confined to the
more differentiated layers. Most importantly, the distribution
of both factors overlapped with the expression of SPRR2A.
Because both octamer and Ets binding sites in the promoter are
essential for SPRR2A expression (5), we questioned whether
Skn-1 isoforms and Ese-1 had the potential to cooperate in
SPRR2A transactivation.
Ese-1 Selectively Cooperates with Skn-1a in the Transactiva-
tion of the SPRR2A Promoter—HaCat cells were transfected
with the SPRR2A-luciferase reporter construct (PSG350) to-
gether with increasing amounts of the different transcription
factors either alone or in various combinations (Fig. 5). The
total amount of transfected expression plasmid was kept con-
stant by compensating with the empty vector. Skn-1a, Skn-1d1,
and Ese-1 alone induced the SPRR2A promoter 3–4-fold at
saturation. However, cotransfections of Skn-1a and Ese-1 acti-
vated the same promoter in a dose-dependent manner up to
8-fold, suggesting functional cooperativity between these two
transcription factors (Fig. 5A). Such synergy was not found in
combinations of Skn-1d1 with Ese-1 (Fig. 5B) nor with Skn-1a
and Ets-2 (Fig. 5C), another Ets transcription factor previously
implicated in keratinocyte terminal differentiation (30). Appar-
ently, only Skn-1a can specifically cooperate with Ese-1 in the
activation of the SPRR2A gene.
Fig. 5D shows the effect of Skn-1d1, Skn-1d2, or Ets-2 on the
cooperative activation of the SPRR2A promoter by Skn-1a and
Ese-1. Although neither Skn-1d2 nor Ets-2 was able to affect
the cooperativity between Skn-1a and Ese-1, a clear drop in
promoter activity was observed when Skn-1d1 was included.
Apparently Skn-1d1 is able to compete with Skn-1a for pro-
moter binding even in the presence of Ese-1, resulting in a
complete abrogation of the synergistic effect. In the case of
Ets-2 the situation is different; Ets-2 can at least partially
down-modulate the activity of Skn-1a in the absence of Ese-1
(Fig. 5C) but not in its presence (Fig. 5D). Furthermore, it is
shown that mutations in either Ets (PSG390) or the octamer
binding site (PSG527) resulted in a complete inhibition of
SPRR2A promoter activity, in agreement with our previously
published results (5).
Taken together, our results show that although both Skn-1a
and Skn-1d1 could transactivate the SPRR2A promoter, only
Skn-1a was able to functionally cooperate with Ese-1, resulting
in enhanced transactivation. Skn-1d1 was able to counteract
this functional cooperativity.
DISCUSSION
In this study, we have identified and characterized three
isoforms of the human Skn-1/Oct-11 gene and assessed their
ability to regulate the human SPRR2A gene. The promoter of
this gene has been well characterized in the past, and its
activation during keratinocyte differentiation has been well
documented. It encompasses an octamer binding site, that is
recognized by Skn-1 and is essential for promoter activity to-
gether with three other transcriptional control elements bound
by, respectively, the Ets, Irf, and Klf transcription factor fam-
ilies (5). Among these, only the Ets binding activity has previ-
ously been identified as the epithelial-specific Ets factor, Ese-1
(18). Our previous finding, that destruction of a single binding
site results in a complete loss of promoter activity, has stressed
the importance of signal integration and transcription factor
cooperativity in the regulation of this gene (5). Here, we have
FIG. 4. A, semiquantitative RT-PCR
analysis of Skn-1, Ese-1, SPRR2A, and
GAPDH expression in various human tis-
sues and cells. RNA isolated from total
skin (lane 1), isolated epidermis (lanes
2–5), foreskin (lane 6), cultured primary
keratinocytes (lane 7), cervix (lane 8), and
uterus (lane 9) were analyzed with
SPRR2A, Ese-1, GAPDH, and isoform-
specific Skn-1 primers. PCR was per-
formed with 25, 30, and 35 cycles, and
products were either detected with gene-
specific probes (Skn-1 isoforms and
SPRR2A) or by direct ethidium bromide
staining (Ese-1 and GAPDH). For
GAPDH only the 30-cycle product is
shown. B, in situ hybridization performed
with digoxigenin-labeled Skn-1-, SPRR2-,
and Ese-1-specific RNA probes. A foreskin
section was analyzed with sense (a, c, e)
and antisense (b, d, f) probes. Bar,
100 m.
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used this well documented facet of SPRR2A regulation to an-
alyze the regulatory abilities, including possible synergistic/
antagonistic activities, of the three different Skn-1 isoforms
that we have identified.
The human Skn-1 gene produces three mRNA species, en-
coding proteins with various N termini (Fig. 6A). The two
shorter mRNA variants are the result of internal promoter
usage and initiate within introns 5 and 7. The observation that
the three transcripts are differentially expressed in various
skin samples and in cultured human keratinocytes (Fig. 4A)
indicates that the corresponding promoters function independ-
ently and are subjected to selective regulation. Although the
Skn-1d1 and Skn-1d2 variants originate within introns, termi-
nation codons prevent the addition of specific N-terminal (“in-
tron”-encoded) sequences to the proteins. Consequently, Skn-1d1
and Skn-1d2 can be viewed as N-terminal deletions of Skn-1a.
Skn-1a, which encodes the full-length protein, is identical to
the mRNA previously described by others (29) and is highly
homologous to its rat and mouse orthologues (13, 14). Skn-1a
transcripts are expressed in all human skin samples analyzed
FIG. 6. A, schematic representation of the various Skn1 isoforms identified in this study. The POU-specific domain (POU-S), the POU-
homeodomain (POU-HD), and the pointed-like domain (PLD) are represented. The amino acid numbering corresponds to the Skn-1a isoform. B,
comparison of the N-terminal region (amino acids 35–121) of Skn-1a with the sterile  motif/pointed domains of Ets-1 and p73-. Identical and
similar amino acid residues are highlighted in gray, and the predicted -helices in Skn-1a (3D-PSSM) and those in the resolved structures of Ets-1
(37) and p73 (38) are boxed. As a reference -helices in Ets-1 are numbered H1-H5.
FIG. 5. Transcription factor cooperativity and antagonism during SPRR2A gene regulation; cotransfection of the SPRR2A-luciferase reporter
construct (5 g) with the indicated total amounts (g) of expression plasmids for Skn-1a and/or Ese-1 (A), Skn-1d1 and/or Ese-1 (B), and Skn-1a
and/or Ets-2 (C). When more than one transcription factor was transfected in the same mixture, the plasmids were always added in equal amounts.
The total amount of transfected expression plasmid was kept constant at 2 g by compensating with empty vector. D, cotransfection of the wild
type (pSG350) or mutant (octamer site, pSG527; Ets site, pSG390) SPRR2A promoter constructs with Skn-1a/Ese-1 and the indicated transcription
factor expression plasmids. Transfection and luciferase measurements were as described previously (28).
Skn-1 Isoforms and Combinatorial Gene Regulation 17797
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 8, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(Fig. 4A). The higher level of expression in epidermal samples
(lanes 2–5) as compared with a total skin preparation (lane 1)
correlates with the epidermal expression of this gene (Fig. 4B).
Our analysis clearly shows that SPRR2A expression is not
strictly linked with either Skn-1A or Ese-1 expression, but it
clearly correlated with the presence of both factors. For in-
stance, low levels of Ese-1 in uterus do not induce SPRR2A
expression due to the absence of Skn-1a (Fig. 4A, lane 9).
However, weak expression of Skn-1a can be compensated by
the presence of Ese-1 and results in efficient SPRR2A expres-
sion in cultured keratinocytes and cervix (lanes 7–8). These in
vivo expression data are in line with our transient transfection
experiments, which have established cooperativity of Skn-1a
and Ese-1 in SPRR2A promoter transactivation (Fig. 5) and
corroborate the previously identified necessity for signal inte-
gration in the regulation of SPRR2A (5).
Skn-1d1 did not have the ability to synergize with Ese-1.
Because Skn-1a and Skn-1d1 exhibited comparable DNA bind-
ing activities with the SPRR2A octamer site, the functional
cooperativity between Skn-1a and Ese-1 is likely to be medi-
ated by a specific domain in Skn-1a, which is not present in
Skn-1d1. Hence, the 122-amino acid N-terminal part of Skn-1a,
which is absent in Skn-1d1 (Fig. 6A), was screened for possible
structural domains by using 3D-PSSM (31), a fold recognition
program at Imperial Cancer Research Fund (London) (www.
sbg.bio.ic.ac.uk/3dpssm). This search has revealed between
amino acids 35 and 121 a region with significant similarity to
the canonical sterile  motif/pointed domain (Fig. 6B). This
fold, which is found in many different proteins, including for
instance the Ets and p53 transcription factor families, func-
tions essentially as a protein-protein interaction interface (32,
33). It might seem tempting to speculate that the pointed-like
domain (PLD) in Skn-1a interacts directly with the Ese-1
pointed domain. However, such an interaction would not ac-
count for the highly specific cooperativity between Skn-1a and
Ese-1 that we have observed. Ets-2 also contains a pointed
domain; it has the ability to bind to the SPRR2A Ets site, but
it does not synergize with Skn-1a. Consequently, it seems more
likely that the Skn-1a pointed-like domain contacts a protein
domain in Ese-1, which is specific for this factor.
The human Skn-1d1 mRNA is conserved among rodents and
primates; however, its coding potential has clearly changed
during evolution. Although in primates the region encoded by
intron 5 is not translated (due to in-frame termination codons),
it encodes in rat and mouse an N-terminal 32-amino acid do-
main (Fig. 6A) that is responsible for the inhibitory activity of
the Skn-1i isoform (13). Skn-1d1 did also inhibit SPRR2A pro-
moter activity in the presence of Skn-1a and Ese-1 (Fig. 5D),
although it had the ability to activate the same promoter when
present on its own (Fig. 3). Furthermore, in our in vivo analy-
sis, high Skn-1d1 expression was inversely related to high
SPRR2A expression. For instance in the epidermal samples of
lanes 2, 3, and 5, where high expression of Ese-1, Skn-1a, and
Skn-1d1 is monitored, expression of SPRR2A is clearly lower
than in foreskin (lane 6), where high expression of Skn-1a and
Ese-1 contrasts with low expression of Skn-1d1. Similarly, com-
parison of lanes 7 and 8 (cultured keratinocytes and cervix)
reveals that similar levels of Skn-1a and Ese-1 lead to lower
expression of SPRR2A in the cultured cells (lane 7) due to the
presence of Skn-1d1. The mechanisms by which hSkn-1d1 and
mSkn-1i inhibit gene expression differ, however, fundamen-
tally. Whereas the mSkn-1i inhibitory domain acts in cis and
inhibits DNA binding (13), the human counterpart has the
same DNA binding affinity as Skn-1a. Due to this property it
can compete with Skn-1a for octamer binding and interfere in
this way with the cooperative activation of SPRR2A by Skn-1a
and Ese-1. The differential effect of Skn-1d1 on SPRR2A ex-
pression in the presence or absence of Skn-1a/Ese-1 is also
interesting from a different point of view. It might actually
shed light on several unexplained findings concerning the rel-
ative transactivation potential of Skn1a and various truncated
constructs, including an N-terminal deletion (29, 34). In these
experiments the outcome depended greatly on the specific pro-
moter that was tested. Although the N-terminal deletion of
Skn-1a induced K10 and HPV1a promoter activity, no discern-
ible effect was observed on HPV-18, and K14 was inhibited.
Our results suggest that such variable outcomes can be ex-
pected and that they are likely to depend mainly on the specific
transcription factor occupancy of the promoter that is analyzed.
This is especially true for promoters subjected to strict com-
binatorial gene regulation, such as SPRR2A (5) and most
likely also for the various promoters mentioned above. Con-
sequently, to be able to fully appreciate the outcome of tran-
scription factor truncation experiments, a reasonable knowl-
edge of the regulatory configuration of the promoter that is
analyzed is a prerequisite. A similar complexity has also
recently been observed for the profilaggrin promoter and is
discussed by the authors (7).
The human Skn-1d2 isoform codes for two proteins lacking
the first 27 or 53 amino acids of the POU-specific domain,
whereas the POU homeodomain is left intact (Fig. 6A). It has
previously been shown that both subdomains are required for
DNA binding (35). This probably explains why Skn-1d2 neither
bound to the SPRR2A octamer site nor affected promoter ac-
tivity. However, Skn-1d2 was widely expressed, with tran-
scripts detected in all skin samples analyzed. This feature
suggests that Skn-1d2 might have a physiological role, which
does not depend on DNA binding. Indeed, POU domain pro-
teins have been shown to regulate transcription also through
protein-protein contacts, in a DNA binding-independent man-
ner. These interactions are often mediated by the POU-specific,
the POU-homeodomain, or both domains and target other tran-
scription factors, co-regulators, basal factors, and chromatin
components (for a recent review, see Ref. 36). For instance,
down-regulation of keratin 14 is mediated by the POU domain
of either Skn-1a or Oct-6 and does not involve DNA binding to
the K14 promoter (34). In the case of Oct-1, several protein-
protein interactions are mediated solely via the POU homeodo-
main (36). Consequently, it is possible that the Skn-1d2-en-
coded proteins, which still have intact POU homeodomains,
have the ability to affect gene expression by similar protein-
protein interactions. More experiments will be needed to un-
ravel a possible regulatory function of the Skn-1d2 isoforms.
Our work describes for the first time a functional interaction
between the Skn-1a and Ese-1 transcription factors. The dif-
ferential cross-talk of Skn-1a and Skn-1d1 with Ese-1 high-
lights the complexity of combinatorial gene regulation during
keratinocyte terminal differentiation. The strict dosage of
Skn-1 isoforms is likely to guarantee both the fine-tuning of the
process of epidermal maturation and its adaptation to external
and environmental hazards.
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